Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Feb 12, 2008
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged \>= 40 years old
- • Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
- • Functional capacity class of I-III
- Exclusion Criteria:
- • Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
- • Acute joint trauma at index joint within the past 3 months with active symptoms
- • Score of \>=20 on PHQ-9 or score of \>=1 on PHQ-9 item i
- • Use of mobility assisting device for \<6 weeks or use of walker
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Naples, Florida, United States
Chicago, Illinois, United States
Tulsa, Oklahoma, United States
Altoona, Pennsylvania, United States
Brooklyn, New York, United States
Phoenix, Arizona, United States
Dallas, Texas, United States
Danville, Virginia, United States
Albuquerque, New Mexico, United States
San Diego, California, United States
Warwick, Rhode Island, United States
Pembroke Pines, Florida, United States
Long Beach, California, United States
Deland, Florida, United States
Greer, South Carolina, United States
Paramount, California, United States
New York, New York, United States
Johnson City, Tennessee, United States
Las Vegas, Nevada, United States
Anaheim, California, United States
Mount Pleasant, South Carolina, United States
Anniston, Alabama, United States
Evansville, Indiana, United States
Edison, New Jersey, United States
Layton, Utah, United States
Jenkintown, Pennsylvania, United States
Saint Petersburg, Florida, United States
Columbus, Ohio, United States
Newtown, Pennsylvania, United States
Miami, Florida, United States
Charleston, South Carolina, United States
South Plainfield, New Jersey, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials